Dexcom (DXCM) Hits A 52-Week High: What's Driving The Stock?
Zacks Investment Research | Nov 24, 2019 08:37PM ET
On Nov 22, shares of Dexcom (NASDAQ:DXCM) scaled a new 52-week high of $223.52, closing the session marginally lower at $221.85. In fact, the stock has rallied nearly 44.9% since its third-quarter earnings announcement on Nov 6.
Rising volumes across all channels, strong patient additions, increasing global awareness of the benefits of real-time CGM and impressive full-year guidance prompted the rally.
Let us take a closer look at the factors driving growth.
Robust Q3 Earnings
The company exited the third quarter on a promising note, with better-than-expected earnings and revenue numbers. International revenues improved 36.1% year over year during the quarter. Per management, international growth was strong, opening up great opportunity on improving global access and awareness.
Gross profit in the quarter rose a stupendous 46.4% year over year.
The company reported operating income of $56 million, compared with the year-ago quarter’s $13.9 million.
The lifted revenue outlook for 2019 buoys optimism among investors, indicating the continuation of this bullish trend through the rest of the year.
Other Encouraging Factors
In September 2019, DexCom started selling G6 in Canada and received great response. In early October, the company commenced the shipping of G6 to Medicare patients. The company recently made submission of its G6 Pro product that is expected to be launched in 2020.
Moreover, investors are optimistic about the company’s partnership with Walgreens to ensure that all Medicare patients can fill their prescriptions for DexCom CGM through any of Walgreens’ nationwide retail locations. The company anticipates more growth for the CGM diagnostic tool market.
The market is upbeat about the company being poised to achieve its long-term target on the expansion of the G6 rollout and improved access to CGM. With this growing demand in mind, the company is on track to meet its goal of doubling G6 capacity by 2019-end. The company has been driving the ongoing transition to G6 in additional international markets. Per management, DexCom is making progress toward finalizing G7 CGM system and projects a late 2020 or early 2021 initial launch.
Meanwhile, Dexcom has been having a great run on the bourses in the past year. The stock has rallied 76.1%, higher than the broader Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.